Alyeska Investment Group
PVLA

Alyeska Investment Group’s Palvella Therapeutics PVLA Stock Holding History

Alyeska Investment Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Sell
2,223
-177,699
-99% -$21.6M ﹤0.01% 634
2026
Q1 		$22.4M Buy
+179,922
New +$18.8M 0.06% 309

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Alyeska Investment Group's PVLA Position: Q2 2026 in Review

Alyeska Investment Group reduced its Palvella Therapeutics (PVLA) stake by 99% in Q2 2026, selling an estimated $21.6M and leaving 2,223 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #634.

Alyeska Investment Group first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. The position peaked at $22.4M in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Alyeska Investment Group held 2,223 shares of Palvella Therapeutics worth $340K as of Q2 2026.
  • Alyeska Investment Group sold 177,699 Palvella Therapeutics shares in Q2 2026, an estimated $21.6M.
  • Palvella Therapeutics made up ﹤0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #634 holding.
  • Alyeska Investment Group first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Alyeska Investment Group's Palvella Therapeutics position peaked at $22.4M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.